3rd DCT, HYBRID & CENTRALISED CLINICAL TRIALS WORLD CONGRESS 2027 EUROPE
Where Innovation, Collaboration and Human‑‑Centred Design Meet to Transform Clinical Research
Thursday 25th - Friday 26th February 2027
Facilitate Live is very pleased to welcome you to our upcoming 3rd Decentralized, Hybrid, Centralised Clinical Trials World Congress 2027 Europe.
The 3rd DCT, Hybrid & Centralised Trials World Congress 2027 Europe brings together a global community united by a common purpose: to shape a future where clinical research is more accessible, more connected and more responsive to the needs of people everywhere. At a time when healthcare is evolving rapidly and expectations around participation, transparency and innovation continue to rise, this Congress offers a space for reflection, collaboration and forward‑looking ambition.
Across two days, leaders from every corner of the research ecosystem will gather not simply to discuss new approaches, but to imagine what is possible when diverse perspectives come together. Whether representing pharma, biotech, CROs, academic institutions, patient organisations or government agencies, each participant contributes a vital piece of the broader vision. The Congress celebrates this diversity of expertise, recognising that meaningful progress in clinical research can only be achieved when all voices are heard and valued.
The programme will explore how modern trial models can be shaped to better serve science and society. It will encourage attendees to look beyond individual technologies or operational processes and instead consider the bigger picture: how we design studies that are more inclusive, how we build systems that are more resilient, and how we create experiences that respect and empower the people who participate. The conversations throughout the event will highlight the importance of flexibility, empathy and shared responsibility in advancing research that truly reflects the world it aims to improve.
A central theme of the Congress is the belief that innovation is not only about new tools, but about new ways of thinking. As digital capabilities expand and remote approaches become more common, the opportunity emerges to rethink long‑standing assumptions about how trials must operate. This gathering encourages attendees to embrace curiosity, challenge convention and explore how modern methods can coexist with trusted foundations. It is an invitation to imagine trial models that are both scientifically rigorous and deeply human‑centred.
Equally important is the recognition that trust and transparency are essential to the future of research. As trials evolve, so must the ways we communicate, engage and collaborate with participants and communities. The Congress emphasises the importance of listening, truly listening, to the experiences, concerns and aspirations of patients. Their voices guide the direction of innovation and remind us that every advancement ultimately serves individuals and families seeking hope, healing and progress.
Throughout the event, attendees are encouraged to connect, share and build relationships that extend beyond the Congress itself. The challenges facing clinical research are complex, but they are also shared. By working together, across sectors, disciplines and borders, we can create trial ecosystems that are more inclusive, more efficient and more capable of meeting the needs of a changing world.
The 3rd DCT, Hybrid & Centralised ClinicalTrials World Congress 2027 Europe is more than a meeting. It is a collective commitment to shaping a future where research is accessible, equitable and grounded in collaboration. It is a celebration of what we can achieve when we unite around a shared vision:
advancing clinical trials that honour both scientific excellence and the people at the heart of every study
We look forward to welcoming you to the 3rd Decentralized, Hybrid, Centralised Clinical Trials World Congress 2027 Europe.
Sincerely yours,
Jocelyn Raguindin
Conference Director
Facilitate Live
Gain The Latest Insights On:
- Evolving clinical trial models that blend decentralised, hybrid and traditional approaches with purpose and flexibility
- Designing participant‑centred studies that strengthen trust, accessibility and engagement
- Digital tools and remote approaches that enhance convenience, connection and data richness
- Cross‑sector collaboration that unites industry, academia, patient groups and public‑sector partners
- Operational strategies that improve consistency, quality and resilience across global research networks
- Modern data collection and oversight practices for an increasingly digital
research landscape - Innovative thinking that challenges convention and inspires more inclusive trial design
- Approaches that support sites and investigators as they adapt to new
technologies and workflows - Communication and transparency practices that deepen participant
confidence and understanding - Opportunities to expand participation through flexible pathways and accessible digital touchpoints
- Shared frameworks that help organisations navigate change while maintaining scientific integrity
- New ways to integrate digital capabilities into long‑term research strategies and portfolios
- Emerging trends shaping the future of global clinical trial delivery and operational excellence
- Collective momentum toward a more connected, equitable and future‑ready clinical research ecosystem
Sponsorship & Exhibit Opportunities
Our event partners and team of experts are recognized for creating and providing unique, innovative events. We open doors and create access to business opportunities for our clients. Our events are forum for discussion, learning, showcasing new technologies, innovations, new products and trends, solutions and concepts.
The impact you make and how you get your message across at our Facilitate Live Events is up to you – we offer packages or tailor made solutions to meet your exact requirements and budget.
By sponsoring a Facilitate Live Event you will be exposed to the following:
- Access to key decision makers
- Direct access to our delegates and attendees
- Increase worldwide awareness of your organisations latest products and services
- Drive and create new business opportunities
- Generate new contacts and renewed interest for your product of expertise
- Be recognised as a key player and a key supporter of your industry sector
- Demonstrate your organization’s commitment
- Demonstrate your excellence as a technical supplier
- Show brand awareness and brand building
- Brand and product endorsements
- Extensive pre-show and post-show coverage
Solution Showcase
Showcase your latest cutting-edge solutions, new products, technology, innovations and trend. Meet face to face with high level decision makers who are in a receptive mindset and actively seeking solutions and services.
As an exhibitor you will gain access to this exclusive captive audience and have the opportunity to:
- Speak to the attendees and demonstrate your product / services at the solution showcase network to captive and receptive key decision makers
- Gain exposure to one of our Facilitate Live
- Host a networking drinks reception or lunch for attendees
- Meet one-on-one with attendees
- Generate a high number of leads with senior decision makers
- Meet your peers and exhibit alongside your competitors
- Present case studies and in-depth information in a solution provider showcase session
- Present case studies and in-depth information in a solution provider showcase session
- Educate the market with your product and technology solutions
Sponsorship & Exhibit Inquiries
Email: Sponsor@facilitatelive.com Tel No: +44 (0)207 193 3485
Who Should Attend:
This Congress will provide information to pharmaceutical and biotech companies, researchers, physicians, institutional review boards (IRBs), patient organizations and advocates, and regulatory agencies about the implementation of Real-World Evidence.
Network with members of the boards, VP’s, Directors, Heads/Chiefs, and Senior Managers of leading Pharmaceuticals and Biotech Companies, Government, CRO’s and Solution Providers Involved in:
Pharma & Biotech
- Heads of Clinical Operations
- Directors of R&D and Clinical Development
- VPs / SVPs of Digital Health & Innovation
- Clinical Trial Strategy Leads
- Medical Directors & Therapeutic Area Heads
- Heads of Patient Engagement & Diversity
- Digital Transformation Leaders
- Evidence Generation & Data Science Leads
Academic & Research Institutions
- Principal Investigators
- Clinical Research Coordinators
- Professors of Clinical Trial Methodology
- Digital Health Researchers
- Biostatisticians & Methodology Experts
- Research Ethics & Governance Leads
Patient Organisations
- Patient Advocacy Leaders
- Community Engagement Managers
- Patient Advisory Board Members
Diversity, Equity & Inclusion Specialists
Government & Public‑Sector Agencies
- Regulatory Affairs Leaders
- Health Policy Advisors
- Digital Health Programme Directors
- Public Health Innovation Managers
- National Research Infrastructure Leads
Technology & Digital Health Innovators
- Founders & CEOs of Digital Health
Companies - Product Leaders in eCOA, eConsent, Wearables & Data Platforms
- AI & Machine Learning Leads
- Patient Experience Designers
CROs & Service Providers
- Clinical Operations Directors
- Project & Programme Leaders
- Digital Trial Delivery Specialists
- Global Study Managers
- Data Management & Analytics Leads
- Patient Recruitment & Retention Strategists
- Technology & Platform Integration Heads
- Global Marketing
- Consultans
- And much more…
Co-located with Patient Centricity & Collaboration World Congress 2027 Europe.
Joint Networking & Exhibit Area.
Website: www.patientcentricityworld.com
- What are the main internal and external barriers to achieving genuine patient centricity?
- What are the key elements for creating an authentically patient-centric company culture?
- What are the challenges and opportunities in shifting to a patient-centric mindset?
- How can a patient-centric culture improve patient access and transparency?
- How can patients be meaningfully involved in the drug development process, from early research to post-market surveillance?
Moderator:
Rosanna Forrest, Director, Patient Engagement, Spectrum Science
Panellists:
Tom Croce, Vice President, Global Patient Advocacy, Jazz Pharmaceuticals
Matthew Reaney, Head of Global Science & Analytics, Patient Centered Solutions (PCS), IQVIA
Danielle Drachmann. Senior Patient Partnering Manager, Thermo Fisher Scientific
Daniel Newman, Patient Advocate, Trueheart International
Jasmine Malone, Group Director for Patient Engagement Content and Storytelling, OPEN Health
Maddie Yorke, Advocacy Services Senior Manager, PPD
(DCT Congress Attendees, please proceed to Cambridge Suite)
Regulation, Collaboration, and Patient Engagement
Amelia Hursey, Strategic Director, Parkinson’s Europe
- MHRA patient involvement strategy
- Current landscape and regulatory considerations
Khadija Rantell, Senior Statistical Assessor, MHRA
- Decentralised elements in Clinical trials
- Industry’s perspectives in adopting DCT elements in Clinical Trials
- How European regulators are enabling DCT adoption
- EFPIA Recommendation Paper on Advancing the Use of Decentralised Elements in Clinical Trials
Elizabeth Theogaraj, Regulatory Senior Group Director, Roche
- Understanding patient challenges: The barriers VWD patients face in clinical research and why their experiences matter.
- Co-creating research from the start: How early patient input ensures trial endpoints reflect what truly matters to the community.
- Making trials more accessible: How decentralized and hybrid models reduce burden and enable broader participation.
- Empowering patients through PPIE: VWD Alliance’s new Patient and Public Involvement & Engagement group gives the community a voice in trial design and decision-making
Cat Wilder, Chair, Von Willebrand Disease Alliance
- Understanding the challenges of delivering rare disease studies
- Study design that considers patient needs
- Where DCT elements offer the most impact
- Looking to the future of DCTs
Catherine Jervis, Head, DCT Market Development – EMEA, MARKEN
- Governance, regulatory and clinical frameworks
- Ethical perspectives
- Operational feasibility
Emma Kinloch, CEO, Salivary Gland Cancer UK
- Scientific rigour and regulatory needs are critical considerations when designing clinical trials and creating protocols.
- How well, though, do we really strike a balance between these needs and the associated burden and complexity they place on our patients and clinical trial sites?
- An exploration of this balancing act, and how we – as a clinical research community – might strive to achieve it through tried and tested methods e.g. patient councils, as well as using disruptive innovations, such as protocol simulations.
Dr Sachin Shah, Clinical Innovation and Digital Solutions Lead, UCB
- A five letter code: what a diagnosis unlocks
- Building momentum: patients, science, collaboration
- From repurposing to personalised medicine: progress, promise, and barriers in ultra-rare treatment development
- Why speed matters: the cost of waiting
Melanie Dixon, Trustee, Cure DHDDS
- Blending virtual and in-person interactions to enhance experience
- Supporting patients through multilingual, digital, and in-clinic channels
- Ensuring safety, adherence, and satisfaction in hybrid environments
- The path toward a unified, inclusive European patient-centric model
Nadya Isack, Patient and Public Involvement (PPIE) Advocate, Founder, Empower Health Initiative CIC,
Person living with Obesity
- Harnessing national participant experience data for real-world patient insights.
- Proactively co-design protocols to minimise participant burden.
- Activating NIHR Agile teams for out-of-hospital delivery.
- Navigating community logistics with dedicated Settings Leads.
Emily Pickering, Specialist Commercial Services Lead, Patient Engagement in Clinical Development, NIHR
Research Delivery Network
- Monitoring acute kidney injuries in nephrotoxic regimens.
- Monitoring fatigue in early phase cancer clinical trials
- Remote PROMs for early phase cancer clinical trials.
- Involvement of patients as co-researchers in remote digitally enabled studies.
Hannah Frost, Clinical Research Scientist, CRUK National Biomarker Centre
Amelia Hursey, Strategic Director, parkinsonseurope.org
Stephen O’Farrell, Executive Director, Patient Engagement, Spectrum Science
Frida Forya, Scientific Alliance Director – Medical Affairs, Roche
- Fostering community engagement and build trust
- Designing a patient-centric, inclusive trials
- Cultivating an inclusive research environment
- Leveraging technology and data
- Adopting regulatory requirements and institutional support
Moderator:
Ify Osunkwo, Chief Patient Officer Rare Disease, Novo Nordisk Rare Disease
Panellists:
Emily Pickering, Patient Engagement in Clinical Development Service Lead, NIHR
Faith Smith, Health Innovation Network, England
Ron Hillel , Associate Director, Clinical Representativeness, Patient Engagement, Novartis
Emma Sutcliffe, Trustee Board Member, SL61A
Anthony Mason, Chief Executive Officer , Sickle Cell Care Manchester
(DCT Congress Attendees, please proceed to Cambridge Suite)
Robert Mitchell-Thain, CEO, PBC Foundation
TECHNOLOGY, OPERATIONS AND FUTURE OUTLOOK
- Turning sustainability goals into measurable action requires, more than intent, it demands collaboration, innovation and integration across every stage of the clinical trials process.
- This presentation and panel discussion brings together leaders from across the clinical research landscape to explore how environmental consideration are being embedded into trial operations in practical, scalable ways.
- The session will explore how to use available tools, such as the clinical trials carbon calculator to assess and reduce trial emissions, discuss how to decarbonise the patient journey from recruitment to retention and build cross-sectoral partnerships to scale sustainable solutions.
Moderator:
Fiona Adshead, Chair, Sustainable Healthcare Coalition
Panellist:
Carly Santer, Strategic Initiatives Project Leader & Sustainability Activator, Bayer UK
Joanna Bell, Project Manager, Sustainable Healthcare Coalition
Hugh Whetherly, Sr Consultant, Product Sustainability Team, ERM
Senior Representative, NovoNordisk
- Identify structural barriers to recruitment and retention in clinical research.
- Develop strategies to enhance recruitment and retention of individuals.
- Feasible approaches to improve patient retention in clinical trials.
Mohamed Sharaf, EMEA Regional Senior Medical Advisor (Immunology), J & J
- This talk explores what it really means to undertake inclusive research in practice, drawing on the work of EDIRA the Equality, Diversity and Inclusive Research Association. Building on three EDIRA events, it traces a journey from
EDIRA-23 Barriers to Inclusion, to EDIRA-24 Building Trust, to EDIRA-25 Book of Doers who are changing how
research is conceived, designed, and delivered - The focus for EDIRA-26
- Throughout, the session the underlying theme will be based on a central question: “Whose voice is it anyway?” challenging delegates to examine whose voices are centred, whose are marginalised, and how lived experience can be recognised as core research expertise rather than an optional add on.
Dr Sondra Butterworth CEO & Founder, RareQoL (Rare Quality of Life) and EDIRA (Equality Diversity and
Inclusive Research Association)
- How electronic healthcare record (EHR) data from UK primary care practice has been used to find and recruit eligible patients for clinical trials, provide follow-up data to ascertain clinical trial outcomes, support safety monitoring and for external control arms.
- Key regulatory considerations around data quality when using EHR data to support clinical trials.
Puja Myles, Director, Clinical Practice Research Datalink (CPRD), M H R A
- This presenation will focus the major challenges clinical trials are facing and how we can turn these challenges into solutions to implement for future trial design.
- This will include learnings from actual patient engagement projects and present how implementing patient perspecitives into DCT and future trial design might be the way forward for DCT and drug development.
Rasmus Hjorth, Head of Communication, James Lind Care
- The session focuses on how participants experience trial burden, support, and value, and why these factors directly impact recruitment, retention, and data quality.
- The session concludes with practical guidance on how sponsors can operationalise patient preferences to move from patient-informed to truly patient-ready trial design and delivery.
Alexandra Charge, CEO and Co-Founder, ISPEP
- This talk will explore how patient insights can guide the design and implementation of decentralized and hybrid clinical trials from early development stages.
- By incorporating the patient perspective, sponsors can adapt endpoints, visit schedules, and participation burden to better reflect real-world needs, improving recruitment, retention, and overall patient satisfaction.
- Practical examples will be shared demonstrating how decentralized approaches — including digital tools, telemonitoring, ePROs, and wearable devices — can be leveraged to enhance efficiency, accessibility, and engagement.
Laura Risueño Ayerbe, Global Patient Affairs, Patient Engagement R&D, Servier
- How are decentralized trials evolving from pilot initiatives to Europe’s new research standard?
- How can decentralized models be effectively integrated with national healthcare systems?
- How can AI and real-world data enhance adaptive and data-driven study design?
- How can transparency and data ownership strengthen patient trust and engagement?
- How will decentralized trials become a core pillar of the European Health Union?
Moderator:
Puja Myles, Director, Clinical Practice Research Datalink (CPRD), MHRA
Panellists:
Lorna Pender, Medical Director, AOP Health Alexandra Charge, CEO and Co-Founder, ISPEP
Dr Sondra Butterworth CEO & Founder, RareQoL and EDIRA
Robert Mitchell-Thain, CEO, PBC Foundation